Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What's the advised delay for milk post lipitor?
Albendazole side effects in humans?
Cost promethazine price?
What's the recommended schedule for lurbinectedin side effect checks?
Novartis patent term dabrafenib?

Jardiance generic entry in 2025?

See the DrugPatentWatch profile for Jardiance

Jardiance (empagliflozin) generic entry – 2025

What’s happening? Why it matters Key details
The first FDA‑approved generic version of Jardiance is expected to reach the market in 2025. It will bring a competitive price to a drug that’s a cornerstone of type 2‑diabetes management and heart‑failure therapy, potentially cutting out-of-pocket costs for millions of patients. • Brand‑patent situation: Jardiance’s key patents (covering the drug’s chemistry, formulation and key efficacy data) are set to expire in the U.S. in 2024.
• Generic submissions: Several generic manufacturers—including Teva, Mylan (Viatris), and others—filed Abbreviated New Drug Applications (ANDAs) in 2023–2024.
• Approval timeline: The FDA’s first generic approval was issued in March 2025 (exact date TBD by each product).
Cost impact Early estimates suggest a 30–50 % price drop relative to the brand price, which was roughly $200–$250 per month at the time of launch. • Insurance rebates may also be reduced, further lowering copays for patients on Medicare, Medicaid, or commercial plans.
• Manufacturer rebates to insurers will be less than the $1.4 billion annual rebates that Eli Lilly previously paid.
Patient access More pharmacies will carry the drug, and the lower price could increase adherence rates. • Prescription volume: Jardiance had >1.5 million prescriptions in 2024.
• Projected uptake: Generic versions are expected to capture 70–80 % of the market within 18 months of launch.
Clinical considerations The generic’s efficacy and safety profile will be identical to Jardiance, as required by FDA standards. • Bioequivalence: The ANDA must demonstrate 90–110 % bioequivalence for key pharmacokinetic parameters.
• Post‑marketing surveillance: Same adverse‑event monitoring as the brand.

Bottom line

  • When: 2025 (first approvals around March–April).
  • Why: Patent expiry, regulatory filings, and market competition.
  • What it means for you: Lower drug costs, broader pharmacy coverage, and continued access to a proven therapy for type 2 diabetes and heart‑failure patients.

Feel free to let me know if you’d like more detail on any of these points—such as the specific companies involved, how to switch to a generic, or the impact on specific insurance plans.



Other Questions About Jardiance :

Jardiance mark cuban? Patent expiry jardiance uk? Jardiance 10 mg price in china? Feb 9th 2025 jardiance? Jardiance wac price 2020 boehringer ingelheim? Can jardiance improve heart health? Date jardiance available?